Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New trial tests gentler surgery for ovarian cysts to save fertility

NCT ID NCT07666412

Disease control Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two surgical techniques for ovarian endometrioma—standard cyst removal (cystectomy) versus a newer method using argon plasma coagulation (APC) to vaporize the cyst lining. The goal is to see which better preserves ovarian reserve, measured by antral follicle count and AMH levels, and reduces recurrence. 146 women aged 18-40 with symptomatic endometriomas will be followed for 12 months after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Argon Plasma Coagulation (APC) ablation procedure
What this could lead to
If APC works better, it could offer a safer surgical option that preserves more healthy ovarian tissue and reduces the risk of infertility after endometrioma surgery.
What could go wrong
This is an early randomized trial with no prior direct comparison, so results may not confirm superiority. There is also a risk of cyst recurrence with APC due to leftover endometriotic tissue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 146 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Symptomatic patients (pain and/or infertility) affected by ovarian endometriomas (unilateral or bilateral). * Age between 18 and 40 years. * Ultrasound diagnosis of one or more mono- or bilateral endometriotic cysts, with a maximum overall diameter (per ovary) ≤ 80 mm and at least one cyst diameter ≥ 20 mm. * Use of hormonal therapy for at least 1 month prior to surgery. * Willingness to undergo follow-up at 40-60 days and 12 months, according to clinical practice. * Willingness to receive postoperative hormonal therapy, according to clinical practice, to minimize the risk of recurrence. * Written informed consent obtained. Exclusion Criteria: * History of unilateral ovariectomy/adnexectomy or hysterectomy. * Ultrasound evidence of other non-endometriotic ovarian cysts requiring surgical removal. * Atypical endometrioma or ultrasound suspicion of malignancy. * Previous surgery on one or both ovaries within 12 months prior to surgery. * Known or suspected active oncological disease. * Inability to undergo transvaginal ultrasound examination (patients with intact hymen).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian endometrioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometriosis ovarian endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian endometrioma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    Bologna, Bologna, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.